CVS Caremark Expanding PGx Testing to Its PBM Customers | GenomeWeb

By Turna Ray

CVS Caremark, the country’s largest pharmacy-services provider, is expanding its pharmacogenomic testing to its pharmacy benefit management customers to predict their response to treatments for cancer, cardiovascular diseases, and HIV, the company said this week.

The program will be put in place through Generation Health, a genetic testing benefit management company launched last year to help insurers, employers, and other PBMs implement genetic testing with in their systems.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.